Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
May 13, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
April 04, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Retains Renmark Financial Communications
March 12, 2019 23:46 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 12, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Kenneth Rainin Foundation Awards Over $2 Million For Collaborative IBD Research Projects
February 04, 2019 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation announced that it has awarded over $2 million in grants through its Synergy Awards program. This program encourages...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
November 13, 2018 07:00 ET
|
Breathtec Biomedical Inc.; Nash Pharmaceuticals Inc.
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)...
Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
November 07, 2018 09:42 ET
|
Biomerica, Inc.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo...
Kenneth Rainin Foundation Awards $2.6 Million for Cutting-Edge IBD Research
October 02, 2018 08:00 ET
|
Kenneth Rainin Foundation
Oakland, California, Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation has awarded $2.6 million through its Innovator Awards program to improve the prediction and prevention of...
Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis
October 01, 2018 07:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
August 02, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...